1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://doi.org/10.2122/gbc.2012.0213
DC FieldValue
dc.titleSolid cancer: Evaluating potential efficacy of epigenetic drugs
dc.contributor.authorKu, C.-S.
dc.date.accessioned2014-12-12T07:55:22Z
dc.date.available2014-12-12T07:55:22Z
dc.date.issued2012-04
dc.identifier.citationKu, C.-S. (2012-04). Solid cancer: Evaluating potential efficacy of epigenetic drugs. Gastric and Breast Cancer 11 (2) : 102-107. ScholarBank@NUS Repository. <a href="https://doi.org/10.2122/gbc.2012.0213" target="_blank">https://doi.org/10.2122/gbc.2012.0213</a>
dc.identifier.issn11097655
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/116891
dc.description.abstractCurrent generation of targeted cancer drugs in the treatment of solid cancers, with the exceptions of trastuzumab and vemurafenib, resistance and disease progression limit the effectiveness of most signal transduction inhibitors available. Epigenomic drugs and microRNAs-based agents represent one of promising categories in clinical development to increase tumor cells sensitivity to combined therapeutics. Here, I discuss latest data and perspectives in overcoming current therapy resistance by treating solid tumors.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.2122/gbc.2012.0213
dc.sourceScopus
dc.typeReview
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.2122/gbc.2012.0213
dc.description.sourcetitleGastric and Breast Cancer
dc.description.volume11
dc.description.issue2
dc.description.page102-107
dc.identifier.isiutNOT_IN_WOS
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.